

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M. 6278-Takeda/Nycomed**

## **SECTION 1.2**

### **Description of the concentration**

On 27 June 2011, Takeda Pharmaceutical Company Limited (“**Takeda**”) notified a proposed concentration pursuant to Article 4(2) of the EU Merger Regulation, by which Takeda proposes to acquire Nycomed A/S (“**Nycomed**”), by way of a purchase of shares.

Takeda is a Japan-headquartered company and Nycomed is a Switzerland-headquartered company and both are active worldwide. Takeda is the parent company of a global group of companies whose activities are divided into three business segments: ethical drug, consumer healthcare and other businesses (including the manufacture and marketing of reagents, clinical diagnostics and chemical products). Nycomed offers a diversified product range focused on branded prescription medicines, consumer healthcare products and a contract manufacturing business.